Epidemiology of Heart Failure with Preserved Ejection Fraction

[1]  Grace Lin,et al.  Right heart dysfunction in heart failure with preserved ejection fraction. , 2014, European heart journal.

[2]  B. French,et al.  Heart Failure With Recovered Ejection Fraction: Clinical Description, Biomarkers, and Outcomes , 2014, Circulation.

[3]  C. Ayers,et al.  Association of cardiorespiratory fitness with left ventricular remodeling and diastolic function: the Cooper Center Longitudinal Study. , 2014, JACC. Heart failure.

[4]  L. Tavazzi,et al.  In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry. , 2014, International journal of cardiology.

[5]  Sanjiv J Shah,et al.  Spironolactone for heart failure with preserved ejection fraction. , 2014, The New England journal of medicine.

[6]  Talicia Tarver,et al.  HEART DISEASE AND STROKE STATISTICS–2014 UPDATE: A REPORT FROM THE AMERICAN HEART ASSOCIATION , 2014 .

[7]  S. Russell,et al.  Incidence and survival of hospitalized acute decompensated heart failure in four US communities (from the Atherosclerosis Risk in Communities Study). , 2014, The American journal of cardiology.

[8]  E. Braunwald,et al.  Impact of Atrial Fibrillation on Exercise Capacity in Heart Failure With Preserved Ejection Fraction: A RELAX Trial Ancillary Study , 2014, Circulation. Heart failure.

[9]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[10]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[11]  W. Hundley,et al.  Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. , 2013, Journal of the American College of Cardiology.

[12]  S. Solomon,et al.  Classification of Acute Decompensated Heart FailureClinical Perspective , 2013 .

[13]  M. Vaduganathan,et al.  Epidemiology of hospitalized heart failure: differences and similarities between patients with reduced versus preserved ejection fraction. , 2013, Heart failure clinics.

[14]  C. Ayers,et al.  Physical Fitness and Risk for Heart Failure and Coronary Artery Disease , 2013, Circulation. Heart failure.

[15]  C. Lam,et al.  How do patients with heart failure with preserved ejection fraction die? , 2013, European journal of heart failure.

[16]  R. D. de Boer,et al.  Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. , 2013, European heart journal.

[17]  S. Solomon,et al.  Classification of Acute Decompensated Heart Failure: An Automated Algorithm Compared With a Physician Reviewer Panel: The Atherosclerosis Risk in Communities Study , 2013, Circulation. Heart failure.

[18]  R. Wachter,et al.  RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study. , 2013, JACC. Heart failure.

[19]  Martin Penicka,et al.  Diagnosis of heart failure with preserved ejection fraction: role of clinical Doppler echocardiography , 2013, Heart.

[20]  R. Wachter,et al.  Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. , 2013, JAMA.

[21]  M. Hori,et al.  Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J‐DHF) , 2013, European journal of heart failure.

[22]  J. McMurray,et al.  What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? , 2012, Journal of the American College of Cardiology.

[23]  E. Braunwald,et al.  Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. , 2012, American heart journal.

[24]  Shannon M. Dunlay,et al.  Longitudinal Changes in Ejection Fraction in Heart Failure Patients With Preserved and Reduced Ejection Fraction , 2012, Circulation. Heart failure.

[25]  S. Solomon,et al.  The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial , 2012, The Lancet.

[26]  R. Luepker,et al.  Sudden cardiac death in heart failure patients with preserved ejection fraction. , 2012, Journal of cardiac failure.

[27]  L. Maier.  New Treatment Options for Late Na Current, Arrhythmias, and Diastolic Dysfunction , 2012, Current Heart Failure Reports.

[28]  Adrian F Hernandez,et al.  Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection Fraction: Prevalence, Therapies, and Outcomes , 2012, Circulation.

[29]  Peter C Austin,et al.  Lifetime Analysis of Hospitalizations and Survival of Patients Newly Admitted With Heart Failure , 2012, Circulation. Heart failure.

[30]  H. Yokoshiki,et al.  Mode of death in patients with heart failure and reduced vs. preserved ejection fraction: report from the registry of hospitalized heart failure patients. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[31]  L. Chambless,et al.  Classification of Heart Failure in the Atherosclerosis Risk in Communities (ARIC) Study: A Comparison of Diagnostic Criteria , 2012, Circulation. Heart failure.

[32]  Robert N. Doughty,et al.  The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. , 2011, European heart journal.

[33]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[34]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[35]  G. Fonarow,et al.  Characterization of heart failure patients with preserved ejection fraction: a comparison between ADHERE‐US registry and ADHERE‐International registry , 2011, European journal of heart failure.

[36]  M. Maurer,et al.  Heart failure with a preserved ejection fraction: what is in a name? , 2011, Journal of the American College of Cardiology.

[37]  Akshay S. Desai,et al.  Heart failure with recovered ejection fraction: a distinct clinical entity. , 2011, Journal of cardiac failure.

[38]  R. Vasan,et al.  Epidemiology and clinical course of heart failure with preserved ejection fraction , 2011, European journal of heart failure.

[39]  D. DeMets,et al.  Factors Associated With Outcome in Heart Failure With Preserved Ejection Fraction: Findings From the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-PRESERVE) , 2011, Circulation. Heart failure.

[40]  D. DeMets,et al.  Factors Associated With Outcome in Heart Failure With Preserved Ejection FractionClinical Perspective , 2011 .

[41]  D. Kitzman,et al.  Exercise Training in Older Patients With Heart Failure and Preserved Ejection Fraction: A Randomized, Controlled, Single-Blind Trial , 2010, Circulation. Heart failure.

[42]  G. Koch,et al.  The anti-ischemic mechanism of action of ranolazine in stable ischemic heart disease. , 2010, Journal of the American College of Cardiology.

[43]  S. Normand,et al.  Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006. , 2010, JAMA.

[44]  E. Schwarz,et al.  Statin Therapy in Patients with Diastolic Heart Failure , 2010, Clinical cardiology.

[45]  R. McKelvie,et al.  Mode of Death in Patients With Heart Failure and a Preserved Ejection Fraction: Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) Trial , 2010, Circulation.

[46]  Harlan M. Krumholz,et al.  Recent National Trends in Readmission Rates After Heart Failure Hospitalization , 2010, Circulation. Heart failure.

[47]  S. Nakatani,et al.  Assessment of myocardial ischemic memory using persistence of post-systolic thickening after recovery from ischemia. , 2009, JACC. Cardiovascular imaging.

[48]  J. McMurray,et al.  The prognostic significance of heart failure with preserved left ventricular ejection fraction: a literature‐based meta‐analysis , 2009, European journal of heart failure.

[49]  Daniel Levy,et al.  Relation of Disease Pathogenesis and Risk Factors to Heart Failure With Preserved or Reduced Ejection Fraction: Insights From the Framingham Heart Study of the National Heart, Lung, and Blood Institute , 2009, Circulation.

[50]  A. Cohen-Solal,et al.  Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). , 2009, Journal of the American College of Cardiology.

[51]  Susan Anderson,et al.  Irbesartan in patients with heart failure and preserved ejection fraction. , 2008, The New England journal of medicine.

[52]  A. Hughes,et al.  Ethnicity and left ventricular diastolic function in hypertension an ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) substudy. , 2008, Journal of the American College of Cardiology.

[53]  V. Roger,et al.  Death in Heart Failure: A Community Perspective , 2008, Circulation. Heart failure.

[54]  J. Bronzwaer,et al.  Diastolic Stiffness of the Failing Diabetic Heart: Importance of Fibrosis, Advanced Glycation End Products, and Myocyte Resting Tension , 2008, Circulation.

[55]  G. Fonarow,et al.  Incident heart failure hospitalization and subsequent mortality in chronic heart failure: a propensity-matched study. , 2008, Journal of cardiac failure.

[56]  Kevin J. Anstrom,et al.  Incidence and prevalence of heart failure in elderly persons, 1994-2003. , 2008, Archives of internal medicine.

[57]  J. Sanderson,et al.  The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction , 2008, Heart.

[58]  W. Frishman,et al.  Use of diuretics in the treatment of heart failure in the elderly. , 2007, Clinics in geriatric medicine.

[59]  K. Dickstein,et al.  How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. , 2007, European heart journal.

[60]  Nancy M Albert,et al.  Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. , 2007, Journal of the American College of Cardiology.

[61]  Serguei V. S. Pakhomov,et al.  Systolic and diastolic heart failure in the community. , 2006, JAMA.

[62]  Ali Ahmed,et al.  Effects of Digoxin on Morbidity and Mortality in Diastolic Heart Failure: The Ancillary Digitalis Investigation Group Trial , 2006, Circulation.

[63]  Peter C Austin,et al.  Outcome of heart failure with preserved ejection fraction in a population-based study. , 2006, The New England journal of medicine.

[64]  V. Roger,et al.  Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.

[65]  C. Yancy,et al.  Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. , 2006, Journal of the American College of Cardiology.

[66]  N. Freemantle,et al.  Perindopril for elderly people with chronic heart failure: the PEP‐CHF study , 1999, European heart journal.

[67]  J. Ornato,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[68]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[69]  F. Magrini,et al.  Prevalence and correlates of left atrial enlargement in essential hypertension: role of ventricular geometry and the metabolic syndrome: The Evaluation of Target Organ Damage in Hypertension study , 2005, Journal of hypertension.

[70]  M. Redfield,et al.  Epidemiology of diastolic heart failure. , 2005, Progress in cardiovascular diseases.

[71]  A. Cohen-Solal,et al.  Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). , 2005, European heart journal.

[72]  D. Burkhoff,et al.  Mechanisms of heart failure with well preserved ejection fraction in dogs following limited coronary microembolization. , 2004, Cardiovascular research.

[73]  T. Fukutomi,et al.  Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. , 2004, The American journal of cardiology.

[74]  C. O'connor,et al.  Racial differences in the outcomes of patients with diastolic heart failure , 2004 .

[75]  W. Gaasch,et al.  Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle. , 2004, The New England journal of medicine.

[76]  L. Sleeper,et al.  Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. , 2004, Journal of the American College of Cardiology.

[77]  M. Metra,et al.  β‐Blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long‐term effects of atenolol vs. nebivolol , 2003, European journal of heart failure.

[78]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.

[79]  Ajay M Shah,et al.  Prognosis in heart failure with preserved left ventricular systolic function: prospective cohort study , 2003, BMJ : British Medical Journal.

[80]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[81]  S. Silver,et al.  Heart Failure , 1937, The New England journal of medicine.

[82]  Daniel Levy,et al.  Long-term trends in the incidence of and survival with heart failure. , 2002, The New England journal of medicine.

[83]  C. Fonseca,et al.  Prevalence of chronic heart failure in Southwestern Europe: the EPICA study , 2002, European journal of heart failure.

[84]  R. Bonow,et al.  Coronary artery disease in patients with heart failure and preserved systolic function. , 2002, The American journal of cardiology.

[85]  E. Antman,et al.  ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary , 2002 .

[86]  R. Vasan,et al.  Defining diastolic heart failure: a call for standardized diagnostic criteria. , 2000, Circulation.

[87]  J. Sanderson,et al.  Comparison of frequencies of left ventricular systolic and diastolic heart failure in Chinese living in Hong Kong. , 1999, The American journal of cardiology.

[88]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[89]  K. Bailey,et al.  Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. , 1998, Circulation.

[90]  W. Aronow,et al.  Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. , 1997, The American journal of cardiology.

[91]  R. Vasan,et al.  The progression from hypertension to congestive heart failure. , 1996, JAMA.

[92]  E. J. Benjamin,et al.  Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. , 1995, Journal of the American College of Cardiology.

[93]  W. Aronow,et al.  Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. , 1993, The American journal of cardiology.

[94]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[95]  H. Black,et al.  Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. , 1990, The American journal of cardiology.